Let’s be real: even with the best intentions, AI systems can reflect our own unconscious biases. As Daniel Kahneman and Amos Tversky famously demonstrated in their groundbreaking work on Prospect Theory, humans are prone to cognitive biases that influence our…
HOME > ARCHIVE
ARCHIVE
- Aricept Generics Approved from 33 Companies
July 25, 2011
- Novo Nordisk's Ultra-Long-Acting Insulin Reduces Incidence of Hypoglycemia
July 25, 2011
- Astellas to Market Pfizer's Caduet from October
July 25, 2011
- DSP to Launch Aricept Generics to Expand Product Lineup in CNS Field
July 25, 2011
- 4,000 Patients Registered with All-Case Survey on Orencia: Bristol-Myers
July 25, 2011
- Astellas Files Suit Against Sandoz Canada Over Generic Version of Prograf
July 25, 2011
- Nippon Chemiphar to Launch Generic Version of Aricept in Nov.
July 25, 2011
- Chugai to Take Safety Measures for Tarceva in Patients with Pancreatic Cancer
July 25, 2011
- Chugai to Fully Recommence Production at Utsunomiya Plant in August
July 25, 2011
- Nichi-Iko to Copromote Radicut Generic with sanofi-aventis
July 25, 2011
- Therapy Using Human Stem Cells to Be Covered by Health Insurance for First Time
July 25, 2011
- Committee Starts Discussing Relief System for Victims of Health Hazards Caused by Anticancer Drugs
July 18, 2011
- Positive Results for Central Neuropathic Pain with Lyrica in PIII Trial: Pfizer
July 18, 2011
- SymBio Licenses Rigosertib from Onconova for MDS
July 18, 2011
- Takeda Recalls Actos, Competact in France
July 18, 2011
- Combined with Insulin, Lixisenatide Decreases HbA1c
July 18, 2011
- Hisamitsu to Launch Norspan Tape in Early August Aiming for ¥1.3 Bil. Sales in FY2011
July 18, 2011
- Senju Files for Glaucoma Treatment Seen as Next-generation Strategic Product
July 18, 2011
- Eisai to Accelerate Biomarker Research with Its Subsidiary EIDIA
July 18, 2011
- Roche Returns Overseas Development, Marketing Rights for SGLT-2 Inhibitor to Chugai
July 18, 2011
ページ
As Japan approaches the Fiscal System Council’s “autumn recommendation,” a notable shift is taking shape. The Ministry of Finance (MOF),…
Japan is considering a new approach to its “special” market expansion re-pricing that would exclude drug sales tied to private…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…